Parliament of The Bahamas ~ Stem Cell Bill Debate ~ July 03, 2013 Morning Parliament of The Bahamas Stem Cell Bill Debate Wednesday, July 03, 2013 Morning Session . By: abetterbahamas … Continue reading →

San Diego, CA (PRWEB) July 10, 2013 Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedicas lead product Stemedyne-MSC. These specially formulated ischemic adult allogeneic mesenchymal stem cells have been manufactured at Stemedicas cGMP compliant facility and have been successfully used to treat patients in an ischemic stroke study: A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Treatment Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke. The primary goal of the Phase I study was to assess the safety and tolerability of treatment with Stemedyne-MSC as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurologic examinations in patients with a clinical diagnosis six months post ischemic stroke. The secondary goal was to assess the clinical effects of treatment on neurologic, functional, and motor deficits. Fifteen patients were treated in this dose escalation Phase I study. Patients received one dose of Stemedyne-MSC via intravenous administration. An Independent Data Safety Monitoring Board reviewed safety … Continue reading →

Research | Policy | Events | Funding | Trend watch | Coming up Jasons quest ends NASA last week decommissioned the long-running ocean-observation satellite Jason-1, following a terminal system failure. The successful mission had exceeded its nominal lifetime by more than six years. Equipped with instruments that measured tiny changes in sea-level heights, the satellite has orbited Earth more than 53,500 times since its 2001 launch. French and US ground stations lost contact with Jason-1 on 21 June, and subsequent attempts to repair its last remaining transmitter proved unsuccessful. A technically advanced successor mission, Jason-2, has been in orbit since 2008; Jason-3 is scheduled for launch in 2015. Polio vaccines Countries in and near the Horn of Africa, including Ethiopia and Yemen, have launched emergency polio-immunization campaigns in response to an ongoing outbreak. The outbreak, traced to viruses from northern Nigeria, is centred in the Banaadir region of Somalia, which includes Mogadishu. Officials from the World Health Organization have recorded 48 cases of polio in Somalia and Kenya since April. Jean Revillard/Rezo.ch/SOLAR IMPULSE Solar plane completes coast to coast The first aeroplane to fly day and night powered only by solar energy landed in New York city on 6July after … Continue reading →

The Food and Drug Administration (FDA) has ordered the registration of human stem cell and cell-based or cellular therapies in the country. "Pursuant to Administrative Order 2013-0012 known as 'Rules and Regulations Governing the Accreditation of Health Facilities Engaging in Human Stem Cell and Stem-Cell Based or Cellular Therapies in the Philippines' strengthening of the regulatory framework to ensure access to safe and quality health facilities engaging in human stem cell and cell-based or cellular therapies in the Philippines has been promulgated," the FDA said. It said the circular "does not cover cellular or cell-based therapeutic products intended to replace blood volume or alter the coagulative properties of blood." The order also does not cover human embryos for research, human embryonic stem cells, aborted human fetal stem cells and plant parts labeled as stem cell as the creation, importation, promotion and marketing of these products are banned in the country. Stem-cell based products of animal origin are also prohibited from being registered with the FDA. Under the guidelines, companies have to submit various documents, including the good manufacturing practice certificate of the stem-cell based manufacturer, information of the product and its manufacture and scientific evidence to support each claimed indication, … Continue reading →